drugset / Trial / NCT00642356

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

NCT00642356

Phase 4 Terminated 14 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's disease.

Timeline

Start
2008-03
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Entacapone Small molecule 200 mg Oral
Background Carbidopa Unknown 25 mg Oral
Background Levodopa Small molecule 100 mg Oral

Indications